Acumen Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
Acumen Pharmaceuticals Stock-Based Compensation Growth & History (ABOS)
Acumen Pharmaceuticals's stock-based compensation was $9.9M for fiscal 2025.
View full Acumen Pharmaceuticals company overviewAcumen Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.9M | $217,000 | +2.25% |
| 2024 | 2024-12-31 | $9.6M | $3.5M | +56.79% |
| 2023 | 2023-12-31 | $6.1M | $3.1M | +100.75% |
| 2022 | 2022-12-31 | $3.1M | $2.1M | +232.00% |
| 2021 | 2021-12-31 | $922,000 | $768,000 | +498.70% |
| 2020 | 2020-12-31 | $154,000 | — | — |
Acumen Pharmaceuticals quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | $26,000 | +1.04% |
| Q1 2026 | 2026-03-31 | $2.4M | −$78,000 | −3.15% |
| Q4 2025 | 2025-12-31 | $2.4M | $76,000 | +3.24% |
| Q3 2025 | 2025-09-30 | $2.5M | $123,000 | +5.26% |
| Q2 2025 | 2025-06-30 | $2.5M | $28,000 | +1.13% |
| Q1 2025 | 2025-03-31 | $2.5M | −$10,000 | −0.40% |
| Q4 2024 | 2024-12-31 | $2.3M | $709,000 | +43.39% |
| Q3 2024 | 2024-09-30 | $2.3M | $738,000 | +46.13% |
| Q2 2024 | 2024-06-30 | $2.5M | $949,000 | +62.39% |
| Q1 2024 | 2024-03-31 | $2.5M | $1.1M | +78.71% |
| Q4 2023 | 2023-12-31 | $1.6M | $746,000 | +84.01% |
| Q3 2023 | 2023-09-30 | $1.6M | $760,000 | +90.48% |
| Q2 2023 | 2023-06-30 | $1.5M | $806,000 | +112.73% |
| Q1 2023 | 2023-03-31 | $1.4M | $772,000 | +124.92% |
| Q4 2022 | 2022-12-31 | $888,000 | $523,000 | +143.29% |
| Q3 2022 | 2022-09-30 | $840,000 | $536,000 | +176.32% |
| Q2 2022 | 2022-06-30 | $715,000 | $588,000 | +462.99% |
| Q1 2022 | 2022-03-31 | $618,000 | $492,000 | +390.48% |
| Q4 2021 | 2021-12-31 | $365,000 | — | — |
| Q3 2021 | 2021-09-30 | $304,000 | $265,000 | +679.49% |
| Q2 2021 | 2021-06-30 | $127,000 | $89,000 | +234.21% |
| Q1 2021 | 2021-03-31 | $126,000 | — | — |
| Q3 2020 | 2020-09-30 | $39,000 | — | — |
| Q2 2020 | 2020-06-30 | $38,000 | — | — |
Acumen Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Acumen Pharmaceuticals's stock-based compensation increased from $154,000 to $9.9M, a change of $9.7M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acumen Pharmaceuticals source filings ↗